SCHEMBL3756932

SCHEMBL3756932

CN1CCC(CN(C)c2nc3cc([N+](=O)[O-])ccc3o2)C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.46
NPC1 O15118 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ACHE P22303 1/20 0.41
MAPT P10636 6/20 0.40
ALDH1A1 P00352 5/20 0.40
USP30 Q70CQ3 1/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MCL1 Q07820 2/20 0.39
ATM Q13315 1/20 0.39
POLB P06746 2/20 0.39
SSTR5 P35346 1/20 0.38
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
MMP8 P22894 1/20 0.37
MMP13 P45452 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3747003 0.82 NPC1 (0.41) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL3754197 0.82 RAB9A (0.48) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
Hydrochloric Acid SCHEMBL3753738 0.81 NPC1 (0.40) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL2072749 0.81 MAPT (0.51) RAB9ANPC1SMN1; SMN2ACHEMAPT
SCHEMBL3759165 0.78 ALDH1A1 (0.49) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL2074416 0.76 RAB9A (0.49) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL3748460 0.74 RAB9A (0.47) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL5290458 0.71 MAPT (0.52) SMN1; SMN2MAPTALDH1A1LMNA
SCHEMBL3746058 0.71 RAB9A (0.44) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL3748623 0.71 MCHR1 (0.50) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-07-02 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170913-A1 NOVEL MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R RAB9A 1154/4885NPC1 689/4885SMN1; SMN2 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.